Daily Medication Pearl: Linaclotide (Linzess)


Linaclotide (Linzess) is indicated for irritable bowel syndrome with constipation and chronic idiopathic constipation.

Indication: Linaclotide (Linzess) is a guanylate cyclase-C agonist indicated in adults for treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).


  • Dosing: The recommended dosage in adults for IBS-C is 290 mcg orally once daily. For CIC the recommended dosage 145 mcg orally once daily or 72 mcg orally once daily based on individual presentation or tolerability.
  • Dosage forms: Capsules in 72 mcg, 145 mcg, and 290 mcg.
  • Adverse events: Most common adverse reactions (≥2%) reported in IBS-C or CIC patients are diarrhea, abdominal pain, flatulence, and abdominal distension.
  • Mechanism of action: Linaclotide is structurally related to human guanylin and uroguanylin and functions as a guanylate cyclase-C agonist.
  • Manufacturer: AbbVie, Ironwood


Final_labeling_text_10-2018-AR-updates-LINZESS-clean.pdf (allergan.com)

linzess image - Google Search

Related Videos
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
Medical team -- Image credit: Flamingo Images | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.